People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Invuity, Inc. | — | Other Health Care | Series B | $105.7M | $507.3M | 2011 |
| Satori Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $22.3M | $464.6M | 2012 |
| Cero Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series A | $16.4M | $17.9M | 2025 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2012 |
| QUATRX PHARMACEUTICALS Co | — | Pharmaceuticals | Series A | $14.0M | $434.4M | 2009 |
| Biomimetic Therapeutics, Inc. | — | Biotechnology | Series A | $10.9M | $105.5M | 2009 |
Chris Ehrlich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris Ehrlich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Albert Cha | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| Dana Mead | 1 | 7 |
| Dana G. Mead, Jr. | 1 | 7 |
| David Schnell | 1 | 7 |
| Ilan Zipkin | 1 | 6 |
| Brian Atwood | 1 | 6 |
| James Murphy | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Daphne Zohar | 1 | 4 |
| Anders Hove | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Gregory B. Brown | 1 | 4 |
| Eric W. Roberts | 1 | 4 |
| Gregory T. Lucier | 1 | 4 |
| Kenneth Hayes | 1 | 3 |
| Guy P. Nohra | 1 | 3 |
| Larry Papasan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.